促进风湿病药物依从性试验核心结局指标实施的策略：来自 OMERACT-依从性组的报告。
Strategies to promote implementation of core outcomes for medication adherence trials in rheumatology: A report from the OMERACT-Adherence Group.
机构信息
Faculty of Medicine & Health, School of Clinical Medicine, South West Sydney Campuses, University of New South Wales, Sydney, Australia.
Radboud University Medical Center, Research Institute for Health Sciences, Department of Pharmacy, Nijmegen, the Netherlands.
出版信息
Semin Arthritis Rheum. 2024 Jun;66:152411. doi: 10.1016/j.semarthrit.2024.152411. Epub 2024 Feb 13.
OBJECTIVES
To identify barriers, facilitators, and strategies for future implementation of the OMERACT-Adherence Core Outcome Set (COS) in medication adherence trials for rheumatic conditions.
METHODS
Preliminary Delphi survey findings were discussed at OMERACT 2023, utilising the Consolidated Framework for Implementation Research 2 to identify implementation barriers, facilitators, and solutions.
RESULTS
Implementation strategies included simplifying the COS definitions, making it adaptabile for clinical practice and drug trials, adherence trial training workshops, and collaborating with key stakeholders such as payers and other COS developers.
CONCLUSION
Ongoing collaboration with individuals and organisations within and beyond rheumatology ensures broader applicability of OMERACT-Adherence COS.
目的
确定在风湿疾病药物依从性试验中实施 OMERACT-依从性核心结局集（COS）的障碍、促进因素和策略。
方法
在 2023 年 OMERACT 会议上讨论了初步德尔菲调查结果，利用实施研究综合框架 2 来确定实施障碍、促进因素和解决方案。
结果
实施策略包括简化 COS 定义，使其适应临床实践和药物试验，举办依从性试验培训研讨会，以及与支付方和其他 COS 开发者等关键利益相关者合作。
结论
与风湿病学内外的个人和组织持续合作，确保 OMERACT-依从性 COS 具有更广泛的适用性。
Zotero 插件